At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
LJN452 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double Blind, Randomized Placebo Controlled Crossover Multiple Dose Study of LJN452 to Assess Safety, Tolerability and Efficacy in Patients With Primary Bile Acid Diarrhea (pBAD).
In Brief
A Phase 2 clinical trial evaluating LJN452 and Placebo to LJN452 for Primary Bile Acid Diarrhea. Completed, enrolled 20 participants across 4 sites in 2 countries.
Detailed Summary
The purpose of this study is to determine whether LJN452 improves the symptoms of bile acid diarrhea and to assess its safety and tolerability profile in patients with primary bile acid diarrhea (pBAD) to guide decision-making regarding further clinical development in this indication.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Bile Acid Diarrhea
CountriesUnited Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJan 2016
First PostedMar 2016
Primary CompletionJan 2018
TodayJul 2026
First PostedMar 18, 2016
Enrollment StartJan 16, 2016
Primary CompletionJan 25, 2018
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 10.3 years ago
Interventions
LJN452drug
Capsules containing LJN452
Placebo to LJN452drug
Capsules containing placebo to LJN452